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Eﬀ ect of rosiglitazone on the frequency of diabetes in 
patients with impaired glucose tolerance or impaired fasting 
glucose: a randomised controlled trial 
The DREAM (Diabetes REduction Assessment with ramipril and rosiglitazone Medication) Trial Investigators*
Summary 
Background Rosiglitazone is a thiazolidinedione that reduces insulin resistance and might preserve insulin secretion. 
The aim of this study was to assess prospectively the drug’s ability to prevent type 2 diabetes in individuals at high risk 
of developing the condition. 
Methods 5269 adults aged 30 years or more with impaired fasting glucose or impaired glucose tolerance, or both, and 
no previous cardiovascular disease were recruited from 191 sites in 21 countries and randomly assigned to receive 
rosiglitazone (8 mg daily; n=2365) or placebo (2634) and followed for a median of 3 years. The primary outcome was 
a composite of incident diabetes or death. Analyses were done by intention to treat. This trial is registered at 
ClinicalTrials.gov, number NCT00095654. 
Findings At the end of study, 59 individuals had dropped out from the rosiglitazone group and 46 from the placebo 
group. 306 (11·6%) individuals given rosiglitazone and 686 (26·0%) given placebo developed the composite primary 
outcome (hazard ratio 0·40, 95% CI 0·35–0·46; p<0·0001); 1330 (50·5%) individuals in the rosiglitazone group and 
798 (30·3%) in the placebo group became normoglycaemic (1·71, 1·57–1·87; p<0·0001). Cardiovascular event rates 
were much the same in both groups, although 14 (0·5%) participants in the rosiglitazone group and two (0·1%) in the 
placebo group developed heart failure (p=0·01).
Interpretation Rosiglitazone at 8 mg daily for 3 years substantially reduces incident type 2 diabetes and increases the 
likelihood of regression to normoglycaemia in adults with impaired fasting glucose or impaired glucose tolerance, or 
both.
Introduction 
Type 2 diabetes mellitus aﬀ ects about 5% of adults 
worldwide; this prevalence is rising rapidly.1 People with 
type 2 diabetes are at high risk of serious eye, kidney, 
nerve, and vascular complications, which cause 
substantial morbidity and mortality. People with 
impaired fasting glucose or impaired glucose tolerance 
are asymptomatic but are at high risk of future diabetes 
and vascular disease.2 
Type 2 diabetes develops when pancreatic insulin 
secretion is insuﬃ  cient to maintain normal glucose 
homoeostasis. Acarbose and metformin3,4 reduce incident 
diabetes by 25–30%; lifestyle interventions that target diet 
and physical activity4–7 reduce incident diabetes by more 
than 50%, but are diﬃ  cult to sustain. Rosiglitazone is a 
thiazolidinedione that is approved for treatment of 
hyperglycaemia in patients with established type 2 diabetes. 
The drug activates peroxisome proliferator-activated 
gamma receptors, increases hepatic and peripheral insulin 
sensitivity,8 preserves insulin secretion,9 and might 
promote pancreatic β-cell health.10,11 These properties, 
together with data from trials with troglitazone12,13 (another 
thiazolidinedione that has been withdrawn because of 
hepatotoxicity), suggest that rosiglitazone could reduce the 
frequency of diabetes in high-risk individuals. 
The DREAM (Diabetes REduction Assessment with 
ramipril and rosiglitazone Medication) Trial was designed 
to assess prospectively whether rosiglitazone can reduce 
the frequency of diabetes in individuals with impaired 
glucose tolerance or impaired fasting glucose, or both. 
Methods 
Patients 
A detailed description of the design of the DREAM trial 
has been published previously.14 Brieﬂ y, 24 592 people 
aged 30 years or more were assessed for eligibility with a 
75 g oral glucose tolerance test between July, 2001, and 
August, 2003, at 191 sites in 21 countries. Inclusion 
criteria included either impaired fasting glucose (fasting 
plasma glucose concentration ≥6·1 mmol/L and 
<7·0 mmol/L and 2-h plasma glucose concentration 
<11·1 mmol/L during the oral glucose tolerance test) or 
impaired glucose tolerance (fasting plasma glucose 
concentration <7·0 mmol/L and 2-h plasma glucose 
concentration ≥7·8 mmol/L and <11·1 mmol/L). People 
with a history of diabetes (except gestational diabetes), 
cardiovascular disease (including heart failure and known 
low ejection fraction), or intolerance to either angiotensin-
converting enzyme inhibitors or thiazolidinediones were 
excluded. 
In 2003, the steering committee expanded the original 
eligibility criteria from impaired glucose tolerance to also 
include individuals with isolated impaired fasting glucose 
(fasting plasma glucose concentration ≥6·1 mmol/L and 
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<7·0 mmol/L and 2-h plasma glucose concentration 
<7·8 mmol/L) to broaden the generalisability of the study 
results.14 
If deemed to be eligible, patients entered a 17-day 
single-blind placebo run-in period; participants who took 
at least 80% of run-in medication were subsequently 
enrolled for randomisation.
All participants were provided with advice by the local 
research staﬀ  about healthy diets and lifestyle habits to 
reduce diabetes. The study protocol and consent forms 
were reviewed and approved by the ethics committees of 
the participating centres, and all participants provided 
written informed consent.
Procedures 
Eligible patients were randomly assigned (stratiﬁ ed by 
site) by a concealed, computerised telephone random-
isation system to receive either rosiglitazone (4 mg once 
daily for the ﬁ rst 2 months and then 8 mg once daily) or 
matching placebo. The dose of 8 mg per day was chosen 
to achieve maximum ability to identify whether the drug 
prevents diabetes and to ensure that a negative study 
would not be attributed to an inadequate dose. Patients 
were concurrently randomly assigned to receive either 
ramipril (titrated to 15 mg once daily) or matching 
placebo with a 2×2 factorial design. Detailed results for 
the ramipril arm are described elsewhere.15 
Participants attended visits 2 months and 6 months 
after randomisation and every 6 months thereafter. At all 
visits, the importance of healthy diet and lifestyle was 
emphasised, drugs were dispensed, and adherence was 
assessed and reinforced. A 75 g oral glucose tolerance 
test with local fasting and 2-h plasma glucose con-
centration measurements was done after 2 years and at 
ﬁ nal visit, and at other yearly visits local fasting plasma 
glucose and glycated haemoglobin concentrations were 
measured. If at any visit the fasting plasma glucose 
concentration was 7·0 mmol/L or greater or the 
2-h plasma glucose concentration was 11·1 mmol/L or 
greater (ie, suggesting possible diabetes), an oral glucose 
tolerance test was scheduled within the next 3 months to 
either conﬁ rm or refute the diagnosis. If the second 
conﬁ rmatory oral glucose tolerance test was negative, 
participants then had yearly repeat measurements taken 
until the end of the study or until diabetes was diagnosed. 
If the fasting plasma glucose concentration was greater 
than 5·3 mmol/L and less than 7·0 mmol/L, and the 
glycated haemoglobin concentration was more than 93% 
of the upper limit of normal for the assay at any visit at 
which an oral glucose tolerance test was not done, such a 
test was scheduled for the next 6-month visit to test for 
possible diabetes as described above. If diabetes was 
diagnosed during the study and needed pharmacological 
therapy, the study drug was continued and antidiabetic 
agents other than a thiazolidinedione were allowed. 
Individuals who were not diagnosed with diabetes at the 
ﬁ nal active therapy visit entered a washout period to 
assess whether any diabetes-prevention properties of the 
study drug(s) persisted after discontinuation. They were 
switched to single-blind placebo and scheduled for a 
repeat oral glucose tolerance test after 2–3 months 
(results to be reported separately). 
Participants had local measurements of alanine 
aminotransferase (ALT) concentrations every 2 months 
during the ﬁ rst year of therapy; subsequent ALT 
measurements were done at the discretion of the site 
physician. Waist and hip circumference and weight were 
measured and an electrocardiograph was done at study 
entry, after 2 years, and at the end of the study. Blood 
pressure was measured at 2 months, 6 months, 
12 months, and yearly thereafter. 
The composite primary outcome was incident diabetes 
or death from any cause during the active treatment 
period; death was included to account for the possibility 
that diabetes might develop at a diﬀ erent rate in 
individuals who die than in those who survive. Diabetes 
was diagnosed if (1) a locally measured fasting plasma 
glucose concentration of 7·0 mmol/L or greater or 
2-h plasma glucose concentration of 11·1 mmol/L or 
greater during a 75 g oral glucose tolerance test was 
conﬁ rmed by a second test on a diﬀ erent day; (2) a single 
test was consistent with diabetes, no conﬁ rmatory test 
was done, and the masked adjudicator had no reason to 
reject the diagnosis; or (3) a physician diagnosed diabetes 
outside the study and the diagnosis was supported by the 
prescription of an antidiabetic agent and either a fasting 
plasma glucose concentration of 7·0 mmol/L or greater 
or any glucose concentration of 11·1 mmol/L or more. 
Diabetes status and date of diagnosis were established by 
masked adjudication of all relevant data.
18784 excluded 
   17703 not eligible 
        567 withdrew consent 
        514 other 
24592 screened
5269 randomised
2634 analysed
2635 rosiglitazone
   59 no ﬁnal visit 
     22 lost to follow-up  
     37 refused  
654 stopped drug
  46 no ﬁnal visit 
     16 lost to follow-up 
     30 refused 
566 stopped drug 
2634 placebo
2635 analysed
5808 run-in
539 excluded
   159 withdrew consent 
   284 not eligible 
     96 other  
Figure 1: Trial proﬁ le
Data were censored at time of last follow-up for all participants. 
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Secondary outcomes included: (1) regression to normal 
fasting and 2-h post-load glucose concentrations, deﬁ ned 
as a fasting plasma glucose concentration of less than 
6·1 mmol/L and a 2-h plasma glucose concentration of 
less than 7·8 mmol/L; (2) a composite of cardiovascular 
events (myocardial infarction, stroke, cardiovascular 
death, revascularisation procedures, heart failure, new 
angina with objective evidence of ischaemia, or ventricular 
arrhythmia needing resuscitation); (3) individual 
components of this cardiovascular composite; (4) renal 
events and a composite cardiorenal outcome; and (5) 
glucose concentrations. Clinical outcomes were assessed 
by masked adjudication by a committee in accordance 
with prespeciﬁ ed diagnostic criteria.
Statistical analysis 
A sample size of at least 5000 individuals with impaired 
glucose tolerance or impaired fasting glucose was 
estimated on the basis of a predicted incidence of the 
primary outcome in the placebo group of 4·5% or greater 
per year, a mean follow-up exceeding 3 years, a type 1 error 
rate of 5%, 10% subadditivity between the two 
interventions, and 90% power to identify a risk reduction 
of 22% or greater. Interim results were reviewed every 
year by an independent trial monitoring committee whose 
role was to unblind and advise the principal investigators 
if there was evidence of clear beneﬁ t or harm. Statistical 
guidelines for beneﬁ t were a reduction in the primary 
outcome by 4 SD or more in the ﬁ rst half of the trial or 
3 SD in the second half that was maintained during two 
consecutive analyses at least 3 months apart in the original 
cohort of participants with impaired glucose tolerance. 
Guidelines for harm included a sustained excess of 
cardiovascular events or death of 3 SD or more in the ﬁ rst 
half and 2 SD in the second half. The committee also took 
emerging information from other studies into account in 
their deliberations. In April, 2005, the committee informed 
the principal investigators that these criteria had been met 
for the subgroup of participants with impaired glucose 
tolerance in the rosiglitazone arm and unblinded them to 
that arm only. However, the principal investigators and 
the committee agreed that the study should continue 
because the average follow-up was short, the full 2-year 
data were not available, and the long-term safety data were 
inadequate. After its review of all the data in October, 2005, 
as well as new results from a large cardiovascular outcome 
trial of another thiazolidinedione,16 the committee was 
suﬃ  ciently convinced that the study question had been 
clearly and robustly answered that it unblinded the 
principal investigators to the entire study results and 
recommended an accelerated but orderly close-out of the 
DREAM trial. This recommendation was agreed and ﬁ nal 
visits were started about 5 months earlier than originally 
anticipated. 
All results were analysed at the Population Health 
Research Institute at McMaster University (Hamilton, 
Ontario, Canada), on the basis of intention to treat. Cox’s 
proportional hazards models were used to estimate the 
eﬀ ect of rosiglitazone on the hazard of the primary and 
other outcomes (stratiﬁ ed by ramipril allocation) and the 
signiﬁ cance of the eﬀ ect. Interaction of the eﬀ ect of 
rosiglitazone and ramipril on the primary outcome was 
assessed by including an interaction term in the Cox 
model. Individuals for whom diabetes status was 
unavailable at the end of the study were censored at the 
Rosiglitazone group (n=2635) Placebo group (n=2634)
Mean age (years) 54·6 (10·9) 54·8 (10·9)
Women 1536 (58·3%) 1584 (60·1%)
Isolated IGT 1504 (57·1%) 1524 (57·9%)
Isolated IFG 369 (14·0%) 370 (14·1%)
Both IGT and IFG 762 (28·9%)* 740 (28·1%)*
Geographic distribution
North America 1082 (41·1%) 1067 (40·5%)
South America 564 (21·4%) 572 (21·7%)
Europe 549 (20·8%) 555 (21·1%)
India 330 (12·5%) 332 (12·6%)
Australia 110 (4·2%) 108 (4·1%)
Medical history
Gestational diabetes in women 139 (9·1%) 147 (9·3%)
History of hypertension 1159 (44·0%) 1132 (43·0%)
Current or former tobacco use 1157 (43·9%) 1193 (45·3%)
More than three alcoholic drinks per week 556 (21·1%) 503 (19·1%)
Sedentary 696 (26·4%) 717 (27·2%)
Drug use
Aspirin or antiplatelet agent 378 (14·4%) 376 (14·3%)
Thiazide diuretics 246 (9·3%) 267 (10·1%)
Other diuretics or aldosterone antagonist 158 (6·0%) 145 (5·5%)
Angiotensin receptor blocker use 153 (5·8%) 133 (5·1%)
Beta-blocker 470 (17·8%) 442 (16·8%)
Calcium channel blockers 328 (12·5%) 349 (13·3%)
Alpha-blocker 43 (1·6%) 65 (2·5%)
Statin or ﬁ brate 391 (14·8%) 389 (14·8%)
Weight loss drugs 16 (0·6%) 14 (0·5%)
Examination
Weight (kg) 84·8 (19·0) 85·0 (18·9)
Body-mass index (kg/m2) 30·8 (5·6) 31·0 (5·6)
Waist/hip ratio (men; women) 0·96 (0·07); 0·86(0·07) 0·96 (0·07); 0·87 (0·09) 
Waist (cm) (men; women) 101 (14); 96 (14) 102 (13); 96 (14)
Systolic blood pressure (mm Hg) 135·9 (17·9) 136·3 (18·8)
Diastolic blood pressure (mm Hg) 83·3 (10·6) 83·5 (10·9)
Investigations
Mean fasting plasma glucose 
concentration (mmol/L)
5·8 (0·7) 5·8 (0·7)
Mean 2-h plasma glucose concentration 
(mmol/L) 
8·7 (1·4) 8·7 (1·5)
Left ventricular hypertrophy on ECG 118 (4·5) 129 (4·9)
Data are mean (SD) or number (%). ECG=electrocardiograph. IFG=impaired fasting glucose (fasting plasma glucose 
concentration >6·1 mmol/L and <7 mmol/L and 2-h plasma glucose concentration <7·8 mmol/L). IGT=impaired 
glucose tolerance. *One individual in the rosiglitazone group and three in the placebo group who were randomised 
despite a fasting plasma glucose concentration >7 mmol/L were assumed to have developed diabetes on day 1.
Table 1: Baseline clinical and biochemical characteristics of participants
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time of their last glucose measurement. Kaplan-Meier 
curves for the primary and secondary outcome were 
constructed for rosiglitazone and placebo and compared 
with stratiﬁ ed log-rank tests. Statistical heterogeneity of 
treatment eﬀ ects within key subgroups was also assessed. 
The eﬀ ect of study drugs on glucose concentrations was 
assessed by calculating the median fasting and 
2-h plasma glucose concentrations noted at every 
scheduled measurement time. Since an oral glucose 
tolerance test was not done after diabetes was diagnosed, 
and because any post-diabetes fasting plasma glucose 
measurements could have been lowered by diabetes 
management, a calculation of the median or mean values 
with every available measurement would have failed to 
accurately assess the eﬀ ect of the interventions on 
glucose concentrations. Instead, median values were 
calculated by assigning people with diabetes the worst 
rank score for both the 2-h and fasting plasma glucose 
measurements,17 and the groups were compared with a 
Wilcoxon rank-sum analysis. Analysis of variance (with 
adjustment for the baseline value) was used to assess 
diﬀ erences between groups in the mean change in ALT 
after 1 year, and in systolic and diastolic blood pressure 
from the beginning to the end of the trial, and the slope 
of change of body-mass index, weight, waist-to-hip ratio, 
and waist and hip circumference during the course of 
the study. We used SAS version 9.1 (2002) for analyses.
This trial is registered at ClinicalTrials.gov, number 
NCT00095654.
Role of the funding source 
All sponsors were represented on the steering committee 
and, together with the other members, provided feedback 
on study design, analysis, interpretation, and the ﬁ nal 
report. The sponsors had no role in the collection, 
storage, or analysis of the data, and were not involved in 
the decision to submit the data for publication. The 
Steering Committee decided to submit for publication, 
and the Hamilton Project oﬃ  ce had full access to the 
data.
Results 
5269 (21·4%) people with a mean age of 
54·7 (SD 10·9) years (59·2% women) were randomly 
assigned to receive either placebo or rosiglitazone 
(ﬁ gure 1). The baseline characteristics of the participants 
are shown in table 1. Of note, 3028 (57%) participants 
had isolated impaired glucose tolerance, 739 (14%) had 
isolated impaired fasting glucose, and 1502 (29%) had 
both. 
Participants were followed for a median of 3·0 years 
(range 2·5–4·7). During the trial 992 (18·8%) individuals 
experienced the primary outcome: 63 (1·2%) people died 
and 938 (17·8%) people developed diabetes on the basis 
of either study-related glucose concentrations (n=786) or 
other criteria (152). Of the remaining participants, 
3961 completed a ﬁ nal visit, 218 provided a verbal report 
of their diabetes status, and 98 did not respond. Vital 
status could not be ascertained in 105 (2·0%) people by 
the end of the trial; in these individuals, vital status was 
known for 2 years or more in 56 people, in 22 for 
1–2 years, and in 27 for less than 1 year. 
In surviving participants for whom adherence to study 
drug was recorded by the research staﬀ  (2604 individuals 
assigned rosiglitazone and 2600 assigned placebo), 
1868 (71·7%) in the rosiglitazone group and 1952 (75·1%) 
in the placebo group were at least 80% adherent at the 
end of the study; two individuals in the rosiglitazone 
group and one in the placebo group were taking 4 mg 
daily; four receiving rosiglitazone and 16 receiving 
placebo were taking open-label rosiglitazone or 
Years
Cu
m
ul
at
iv
e 
ha
za
rd
Number at risk
Placebo 2634 2470 2150 1148 177
Rosiglitazone 2635 2538 2414 1310 217
Rosiglitazone
Placebo
0·0
0 1 2 3 4
0·1
0·2
0·3
0·4
0·5
0·6
Figure 2: Time to occurrence of primary outcome
Rosiglitazone group 
(n=2635) 
Placebo group 
(n=2634)
HR (95% CI) p
Composite primary outcome* 306 (11·6%) 686 (26·0%) 0·40 (0·35–0·46) <0·0001
Diabetes 280 (10·6%) 658 (25·0%) 0·38 (0·33–0·44) <0·0001
   Diagnosed by FPG/OGTT 231 (8·8%) 555 (21·1%) 0·38 (0·33–0·44) <0·0001
   Physician diagnosed 49 (1·9%) 103 (3·9%) 0·47 (0·33–0·66) <0·0001
Death 30 (1·1%) 33 (1·3%) 0·91 (0·55–1·49) 0·7
Regression (FPG <6·1 mmol/L)† 1330 (50·5%) 798 (30·3%) 1·71 (1·57–1·87) <0·0001
Regression (FPG <5·6 mmol/L)† 1016 (38·6%) 540 (20·5%) 1·83 (1·65–2·04) <0·0001
Cardiovascular events composite* 75 (2·9%) 55 (2·1%) 1·37 (0·97–1·94) 0·08
Myocardial infarction 15 (0·6%) 9 (0·3%) 1·66 (0·73–3·80) 0·2
Stroke 7 (0·3%) 5 (0·2%) 1·39 (0·44–4·40) 0·6
Cardiovascular death 12 (0·5%) 10 (0·4%) 1·20 (0·52–2·77) 0·7
Conﬁ rmed heart failure‡ 14 (0·5%) 2 (0·1%) 7·03 (1·60–30·9) 0·01
New angina 24 (0·9%) 20 (0·8%) 1·20 (0·66–2·17) 0·5
Revascularisation 35 (1·3%) 27 (1·0%) 1·29 (0·78–2·14) 0·3
Myocardial infarction, stroke,   
or cardiovascular death
32 (1·2%) 23 (0·9%) 1·39 (0·81–2·37) 0·2
Data are number (%). *Rows are not mutually exclusive for components of the composite—if a participant had more 
than one component of the composite then they are counted in the relevant row. †Regression implies achieving a 
normal fasting glucose concentration (as deﬁ ned in both rows) and 2-h plasma glucose level. ‡Deﬁ ned as acute 
treatment with at least two of the following criteria: typical signs and symptoms, typical radiological evidence, use of 
diuretics, vasodilators, or inotropes. FPG=fasting plasma glucose. OGTT=oral glucose tolerance test.
Table 2: Primary and other outcomes
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pioglitazone. 752 (28·5%) participants in the rosiglitazone 
group and 641 (24·3%) in the placebo group stopped 
taking their assigned treatment at any time; and 
602 (23·6%) people assigned to receive rosiglitazone and 
517 (20·2%) assigned to receive placebo were not taking 
the allocated drug at their last visit. The most common 
reasons for stopping rosiglitazone and placebo included 
participant refusal (503 [18·9%] in the rosiglitazone 
group and 439 [16·7%] in the placebo group); oedema 
(439 [4·8%] and 41 [1·6%]), physician’s advice (50 [1·9%] 
and 39 [1·5%]), and weight gain (50 [1·9%] and 15 [0·6%]). 
One patient in the rosiglitazone group and three in the 
placebo group stopped because of hypoglycaemia. 
There was no statistical evidence of an interaction 
between the rosiglitazone and ramipril arms of the 
DREAM study for the primary outcomes, secondary 
outcomes, or their components (interaction p>0·11 for 
all; data not shown). The primary outcome of diabetes or 
death was seen in signiﬁ cantly fewer individuals in the 
rosiglitazone group than in the placebo group (hazard 
ratio [HR] 0·40, 95% CI 0·35–0·46; p<0·0001; table 2). 
There was no diﬀ erence in the number of deaths (0·91, 
0·55–1·49; p=0·7) and a large diﬀ erence in the frequency 
of diabetes (0·38, 0·33–0·44; p<0·0001) between the two 
groups (table 2). The event curves for the primary 
outcome diverged by the time of the ﬁ rst assessment 
(after 1 year of follow-up; ﬁ gure 2). 
Eﬀ ects on the primary outcome were much the same 
irrespective of the glycaemic abnormality that was 
present at the time of randomisation. Thus, an HR for 
the primary outcome of 0·30 (0·19–0·49) was recorded 
in individuals with isolated impaired fasting glucose, 
of 0·45 (0·36–0·55) in those with isolated impaired 
glucose tolerance, and 0·36 (0·29–0·43) in those with 
combined impaired fasting glucose tolerance and 
impaired glucose tolerance (p value for heterogeneity 
0·14; ﬁ gure 3). When analysed on the basis of the fasting 
plasma glucose alone (ie, irrespective of whether or not 
impaired glucose tolerance was also present), participants 
with any impaired fasting glucose tolerance (ie, isolated 
impaired fasting glucose or impaired fasting glucose 
plus impaired glucose tolerance) had an HR of 
0·35 (0·29–0·42) for the primary outcome. If impaired 
fasting glucose is deﬁ ned as a fasting plasma glucose of 
5·6 mmol/L to 6·9 mmol/L18 the hazard for these 
participants (who in this study also had impaired glucose 
tolerance) was 0·41 (0·30–0·55). 
The eﬀ ect of rosiglitazone was much the same in all 
regions of the world, diﬀ erent ethnic groups, in both 
sexes, and across all ages (ﬁ gure 3). Rosiglitazone was 
also eﬀ ective irrespective of baseline weight or fat 
distribution, albeit to a diﬀ erent degree. Whereas 
increasing baseline weight or waist-to-hip ratio (ie, 
abdominal fat distribution) predicted a higher frequency 
of diabetes in individuals in the placebo group, this 
relation was not seen in those in the rosiglitazone group. 
Consequently the relative hazard reduction for the 
primary outcome increased from 40% in people whose 
body-mass index was less than 28 kg/m2 to 68% in people 
whose body-mass index was greater than 32 kg/m² (p for 
heterogeneity 0·0004; ﬁ gure 3).
0·2 0·4 0·6 0·8
Favours rosiglitazone Favours placebo
1·0 1·2
Sex
Male
Female
Age
<50 years
60+ years
50–59 years
Location
North America
South America
Europe
India
Australia
Glycaemic abnormality
IIFG
IIGT
IFG+IGT
Weight
<75 kg
75-91 kg
92+ kg
BMI
<28 kg/m2
28–32 kg/m2
33+kg/m2
WHR
<0·81
0·81–0·94
0·95+
Waist circumference
<91·5 cm
91·5–103 cm
104+ cm
Hip circumference
<103 cm
103–112 cm
113+ cm
 
 9·9  0·41 (0·34–0·50)
 7·6  0·38 (0·32–0·46)
 8·4  0·44 (0·35–0·55)
 9·5  0·32 (0·26–0·41)
 7·7  0·45 (0·36–0·57)
 8·8  0·37 (0·30–0·45)
 8·0  0·36 (0·26–0·50)
 8·6  0·38 (0·28–0·52)
 8·7  0·60 (0·43–0·84)
 7·2  0·30 (0·13–0·67)
 7·0  0·30 (0·19–0·49)
 6·1  0·45 (0·36–0·55)
 14·0  0·36 (0·29–0·43)
 6·4  0·55 (0·43–0·70)
 8·2  0·42 (0·33–0·52)
 10·8  0·31 (0·24–0·38)
 6·5  0·60 (0·48–0·77)
 8·6  0·35 (0·28–0·45)
 10·2  0·32 (0·25–0·40)
  6·2  0·56 (0·44–0·72)
 9·1  0·36 (0·28–0·45)
 10·4  0·34 (0·27–0·42)
 6·1  0·60 (0·47–0·77)
 8·7  0·39 (0·31–0·49)
 10·8  0·29 (0·23–0·37)
 7·2  0·53 (0·42–0·67)
 8·7  0·35 (0·27–0·45)
 9·8  0·35 (0·28–0·44)
 
Overall p value for
heterogeneity
0·6
0·09
0·09
0·14
0·002
0·0004
0·009
0·0002
0·03
Placebo
% per year
Hazard ratio
(95%CI)
Figure 3: Eﬀ ect of rosiglitazone on the primary outcome in key subgroups
BMI=body-mass index. IIFG=isolated impaired fasting glucose. IIGT=isolated impaired glucose tolerance. 
WHR=waist-to-hip ratio. 
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A signiﬁ cantly larger number of participants receiving 
rosiglitazone regressed to normoglycaemia (deﬁ ned as 
a 2-h plasma glucose concentration <7·8 mmol/L and 
fasting plasma glucose concentration <6·1 mmol/L) 
than did individuals receiving placebo (1330 indiv-
iduals on rosiglitazone vs 798 on placebo; HR 1·71, 
1·57–1·87; p<0·0001; table 2). The eﬀ ect on re-
gression was also evident when a more stringent 
deﬁ nition of normal fasting plasma glucose con-
centration (<5·6 mmol/L) was used (1·83, 1·65–2·04; 
p<0·0001; table 2 and ﬁ gure 4). 
Both treatment groups had much the same frequency 
of the composite cardiovascular outcome and of every 
component of the composite except for heart failure 
(table 2). There were no cases of fatal heart failure; one 
person in the rosiglitazone group died of a myocardial 
infarction 1 month after a diagnosis of heart failure and 
one person died after a procedure done 2 years after 
stopping treatment with rosiglitazone. Increases in the 
risk of heart failure in the presence or absence of ramipril 
were much the same and were distributed throughout 
the follow-up period (data not shown). 174 (6·8%) of 
2547 people in the rosiglitazone group reported peripheral 
oedema at the ﬁ nal visit versus 124 (4·9%) of 2554 people 
in the placebo group (p=0·003). 
Figure 5 shows the eﬀ ect of rosiglitazone on fasting 
and 2-h plasma glucose concentrations. The median 
fasting plasma glucose concentration was 0·5 mmol/L 
lower in the rosiglitazone group than in the placebo 
group (p<0·0001); the 2-h plasma glucose concentration 
was 1·6 mmol/L lower (p<0·0001). Mean systolic and 
diastolic blood pressure were 1·7 mm Hg and 1·4 mm Hg 
lower, respectively, in the rosiglitazone group than in the 
placebo group (p<0·0001). Furthermore, mean hepatic 
ALT concentrations during the ﬁ rst year of therapy were 
4·2 U/L lower in patients treated with rosiglitazone than 
those in the placebo group (p<0·0001). All results are for 
the ﬁ nal visit apart from the ALT diﬀ erence, which was at 
1 year. Of note, there was no diﬀ erence in the use of 
antihypertensive agents in the two groups during the 
trial. Finally, by the ﬁ nal visit mean bodyweight was 
increased by 2·2 kg more in the rosiglitazone group than 
in the placebo group (p<0·0001). This increase in 
bodyweight in the rosiglitazone group was associated 
with a lower waist-to-hip ratio (p<0·0001) because of an 
increase in hip circumference of 1·8 cm; there was no 
eﬀ ect on waist circumference (ﬁ gure 6). 
Discussion 
This large, prospective, blinded international clinical 
trial shows that 8 mg of rosiglitazone daily, together 
with lifestyle recommendations, substantially reduces 
the risk of diabetes or death by 60% in individuals at 
high risk for diabetes. The absolute risk diﬀ erence 
between treatment groups of 14·4% means that for 
every seven people with impaired fasting glucose or 
impaired glucose tolerance who are prescribed 
rosiglitazone for 3 years, one will be prevented from 
developing diabetes. Moreover, rosiglitazone 
signiﬁ cantly increased the likelihood of regression to 
normoglycaemia by about 70–80% compared with 
placebo. The reduction in diabetes reported here is of 
much the same magnitude as the reduction achieved 
with lifestyle approaches4,5 and greater than the 
reductions reported previously with drugs such as 
metformin4 or acarbose.3 The eﬀ ect on regression is 
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(A) FPG deﬁ ned as concentration <6·1 mmol/L or (B) <5·6 mmol/L. The p value 
for the likelihood that the distribution across categories would have occurred by 
chance using both FPG cutoﬀ s was <0·0001. 
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much the same or larger than that of lifestyle approaches 
or acarbose, but larger than that with metformin, which 
did not promote more regression than placebo.3,4 These 
results support ﬁ ndings from smaller clinical trials of 
troglitazone in people with either impaired glucose 
tolerance12 or women with a history of gestational 
diabetes.13
A consistent reduction in the primary outcome was 
noted in people with impaired fasting glucose and those 
with impaired glucose tolerance, in men and women, in 
all participating regions of the world (consisting of many 
ethnic groups), in patients of all ages, and in participants 
of varying weight and fat distribution. Participants with a 
higher body-mass index or abdominal fat distribution 
who were allocated to receive rosiglitazone all had the 
same 3–4% per year incidence of the primary outcome, 
despite progressively higher rates in the corresponding 
control participants (data not shown); this ﬁ nding 
accounts for the observation of higher risk reduction 
with higher baseline obesity (ﬁ gure 3). Rosiglitazone 
therefore seems to reduce or eliminate the relation 
between increasing obesity and a higher risk of diabetes. 
Several explanations could account for these ﬁ ndings. 
Rosiglitazone might simply reduce the raised glucose 
concentrations of dysglycaemic participants by increasing 
the eﬀ ectiveness of endogenous insulin. If true, the eﬀ ect 
on glucose concentrations should be largely eliminated 
upon withdrawal or washout of the drug; this will be 
formally tested during the post-trial washout period. Data 
from one previous troglitazone trial suggests that the 
beneﬁ ts of a thiazolidinedione persist even after the drug 
is stopped;19 this was not seen in another trial.12 
Alternatively, rosiglitazone could slow the fall in β-cell 
function with time by reducing the physiological demand 
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Figure 6: The eﬀ ect of rosiglitazone on weight and fat distribution
Overall eﬀ ect of rosiglitazone and placebo on the slope of (A) weight and (B) body-mass index, (C) waist-to-hip ratios in all participants, and (D) waist and hip 
separately. p values indicate the diﬀ erences in slope and the markers indicate the mean values for rosiglitazone (square) and placebo (circle) at every time point. 
Weight, waist, and hip circumference were recorded at baseline, 2 years, and study end (3 or 4 years for most participants). NS=not signiﬁ cant.
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for basal as well as prandial insulin secretion (ie, through 
insulin sensitisation) or by a direct β-cell cytoprotective 
eﬀ ect.11 Another explanation is oﬀ ered by the observation 
that the frequency of diabetes was lower in the 
rosiglitazone group than in the placebo group, despite a 
2·2 kg increase in weight in the rosiglitazone group. The 
preferential deposition of fat in the hip versus the 
abdomen and the reduction in ALT concentrations noted 
during the ﬁ rst year of therapy suggests that this modest 
weight gain could have been due to fat accumulation in 
non-visceral compartments and an increase in 
subcutaneous adipocyte mass.20 Such an eﬀ ect could be 
accompanied by increased secretion of adiponectin and 
reduced levels of inﬂ ammatory cytokines, and is 
associated with less diabetes.21,22 
Epidemiological studies and at least one clinical trial of 
people with cardiovascular disease suggest that 
thiazolidinediones might reduce cardiovascular events.16,23 
However, such a reduction was not the focus of this trial 
and the short observation period and low event rates 
(table 2) preclude drawing reliable conclusions with 
regard to the cardiovascular eﬀ ects of rosiglitazone. 
Indeed, the DREAM trial explicitly excluded individuals 
with previously diagnosed cardiovascular disease because 
of clear evidence that ramipril reduced cardiovascular 
events in these individuals.24 The eﬀ ect of rosiglitazone 
on atherosclerosis, measured by sequential carotid 
ultrasounds in a subset of DREAM participants, will be 
reported elsewhere. 
Rosiglitazone had no eﬀ ect on the cardiovascular 
composite outcome, although blood pressure was 
signiﬁ cantly lower in those receiving the drug than those 
receiving placebo. However, as reported in 
thiazolidinedione studies done in people with diabetes,25 
there was a small excess in non-fatal congestive heart 
failure in those receiving rosiglitazone. These ﬁ ndings 
could be explained by the vascular and renal eﬀ ects of 
the drug. Rosiglitazone-mediated vasodilation caused by 
both direct eﬀ ects on blood vessels and increases in 
vascular insulin sensitivity accounts for the modest fall 
in blood pressure.26 Sodium and water retention could 
occur as a result of a direct thiazolidinedione eﬀ ect on 
the renal collecting duct and possibly in response to the 
modest fall in blood pressure.25,27 The resulting ﬂ uid 
overload is probably responsible for congestive heart 
failure in susceptible individuals. The observation that 
the incidence of heart failure with a thiazolidinedione 
was about ten times lower in participants at low risk of 
cardiovascular events in the DREAM trial than in a 
cardiovascular prevention trial of participants at high 
risk16 could be explained by a reduced susceptibility of 
lower risk people to heart failure. Nevertheless, since 
there were only 16 cases of heart failure, this estimate 
needs to be interpreted cautiously and further analyses 
of these data, together with data from other 
thiazolidinedione studies, are indicated to better identify 
people at risk. 
More than 8% of adults worldwide have either impaired 
glucose tolerance or impaired fasting glucose.1 Every year 
about 5–10% of these people will develop diabetes and 
acquire the disease burden related to its diagnosis, 
symptoms, need for surveillance for chronic consequences, 
and associated costs. They will also be at high risk for 
several chronic diseases. The results of this study suggest 
that the addition of rosiglitazone to basic lifestyle 
recommendations substantially reduces the risk of 
developing diabetes by about two-thirds, oﬀ ering a novel 
preventive approach that could be as, or more, eﬀ ective 
and sustained than previously reported lifestyle approaches 
alone.4,5 Balancing both the beneﬁ ts and risks suggests 
that for every 1000 people treated with rosiglitazone for 
3 years, about 144 cases of diabetes will be prevented, with 
an excess of four to ﬁ ve cases of congestive heart failure. 
Finally, the observation that rosiglitazone increased the 
likelihood of regression to normoglycaemia by about 
70–80% suggests that it is treating dysglycaemia as well as 
reducing the frequency of diabetes. Further work is needed 
to establish whether the beneﬁ cial metabolic eﬀ ects seen 
with rosiglitazone will lead to a reduction in cardiovascular, 
renal, retinal, or other serious health consequences.28 
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